Schoenen Sophie, Delbecque Katty, Van Rompuy Anne-Sophie, Marbaix Etienne, Noel Jean-Christophe, Delvenne Philippe, Moerman Philippe, Vergote Ignace, Kridelka Frédéric, Vandewal Aleide, Han Sileny, Goffin Frederic
Gynecology and Obstetrics, University of Liege Central University Hospital, Liège, Belgium.
Pathology Anatomy, University of Liege Central University Hospital, Liège, Belgium.
Int J Gynecol Cancer. 2022 Jun 6;32(6):740-745. doi: 10.1136/ijgc-2021-003312.
To evaluate the added value of a centralized pathology review of the diagnoses of gestational trophoblastic diseases by expert pathologists and its potential impact on clinical management in a prospective multicenter study based on the Belgian Gestational Trophoblastic Diseases Registry.
From July 2012 to December 2020, the two referral centers of the registry were solicited to advise on 1119 cases. Referral pathologists systematically reviewed all of the initial histological diagnoses. Cases initially assessed by expert pathologists were excluded. A total of 867 files were eligible for the study. Concordance between diagnoses of gestational trophoblastic diseases made by general 'non-expert' and expert pathologists was analyzed together with the potential impact of the alterations on clinical management. Expert pathologists were working in an academic setting with high exposure to placental pathology and national recognition.
The rate of discordance between expert and non-expert pathologists for the initial diagnoses was 35%. Almost 95% of complete moles were confirmed by the expert pathologists, but only 61% for partial moles. Compared with previous studies, ancillary techniques (p57 immunohistochemistry, karyotype) were used twice as often by both groups of pathologists in this survey. The diagnosis of gestational trophoblastic neoplasia was altered in 42% of cases. When the initial diagnosis was altered, the clinical relevance of this correction was estimated as down staging, up staging, or not relevant in 65%, 33% and 2% of cases respectively.
Systematic centralized pathological review of gestational trophoblastic diseases modified the diagnosis in a third of cases. The results also show that a change in diagnosis would impact clinical management in 98% of patients.
在一项基于比利时妊娠滋养细胞疾病登记处的前瞻性多中心研究中,评估专家病理学家对妊娠滋养细胞疾病诊断进行集中病理审查的附加价值及其对临床管理的潜在影响。
2012年7月至2020年12月,登记处的两个转诊中心就1119例病例提供了建议。转诊病理学家系统地审查了所有初始组织学诊断。排除最初由专家病理学家评估的病例。共有867份文件符合研究条件。分析了普通“非专家”病理学家和专家病理学家对妊娠滋养细胞疾病诊断之间的一致性,以及诊断改变对临床管理的潜在影响。专家病理学家在学术环境中工作,对胎盘病理学有高度接触且在国内享有声誉。
专家病理学家与非专家病理学家对初始诊断的不一致率为35%。几乎95%的完全性葡萄胎被专家病理学家确诊,但部分性葡萄胎仅为61%。与以往研究相比,本调查中两组病理学家使用辅助技术(p57免疫组化、核型分析)的频率是以往的两倍。42%的病例妊娠滋养细胞肿瘤的诊断发生了改变。当初始诊断改变时,这种校正的临床相关性在65%、33%和2%的病例中分别估计为分期下调、分期上调或无关。
对妊娠滋养细胞疾病进行系统的集中病理审查使三分之一的病例诊断发生了改变。结果还表明,诊断改变将影响98%患者的临床管理。